Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical PatientsAlexander T Cohen, Victor F. Tapson, Theodore E. Spiro et al.|New England Journal of Medicine|2013Cited by 603
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P. Schlaich, Thomas Guldager Lauridsen, Ji‐Guang Wang et al.|The Lancet|2022Cited by 223
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolAlexander Thomas Cohen, Victor F. Tapson, Harry R. Büller et al.|Journal of Thrombosis and Thrombolysis|2011Cited by 120
D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trialAlexander T. Cohen, Paul Burton, Theodore E. Spiro et al.|Journal of Thrombosis and Haemostasis|2014Cited by 115
Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart FailureAlexandre Mebazaa, Alexander T. Cohen, Theodore E. Spiro et al.|Circulation|2014Cited by 70